\n\n\n \n \n\n \n \n \n \n\n\n \n\n \n\n Nov 12, 2009 7:36 AM EST \n\n \n Results From Chelsea Therapeutics' Phase III Trial of Droxidopa in Neurogenic Orthostatic Hypotension to be Presented at 20th Annual International Symposium on the Autonomic Nervous System - GlobeNewswire\n \n \n | \n\n \n\n \n\n \n\n Nov 02, 2009 4:16 PM EST \n\n \n Chelsea Therapeutics Reports Third Quarter 2009 Results - GlobeNewswire\n \n \n | \n\n \n\n \n\n \n\n Nov 02, 2009 7:30 AM EST \n\n \n Chelsea Therapeutics Appoints Dr. William D. Schwieterman Chief Medical Officer - GlobeNewswire\n \n \n | \n\n \n\n \n\n \n\n Oct 28, 2009 9:05 AM EDT \n\n \n Chelsea Therapeutics to Host Conference Call to Discuss Third Quarter 2009 Results - GlobeNewswire\n \n \n | \n\n \n\n \n\n \n\n Oct 27, 2009 7:31 AM EDT \n\n \n Chelsea Therapeutics to Present at the Oppenheimer 20th Annual Healthcare Conference on Wednesday, November 4, 2009 - GlobeNewswire\n \n \n | \n\n \n\n \n\n \n\n Oct 20, 2009 7:31 AM EDT \n\n \n Chelsea Therapeutics Presents Novel, Metabolically Inert Autoimmune Portfolio at the 2009 ACR Annual Scientific Meeting - GlobeNewswire\n \n \n | \n\n \n\n \n\n \n\n Oct 01, 2009 4:01 PM EDT \n\n \n Chelsea Therapeutics to Host Conference Call to Discuss Droxidopa Phase III Results Today At 4:30 PM ET - GlobeNewswire\n \n \n | \n\n \n\n \n | \n
\n\n
\n\n");